Practical synthesis of the therapeutic leads tigilanol tiglate and its analogues.
Ontology highlight
ABSTRACT: Tigilanol tiglate is a natural product diterpenoid in clinical trials for the treatment of a broad range of cancers. Its unprecedented protein kinase C isoform selectivity make it and its analogues exceptional leads for PKC-related clinical indications, which include human immunodeficiency virus and AIDS eradication, antigen-enhanced cancer immunotherapy, Alzheimer's disease and multiple sclerosis. Currently, the only source of tigilanol tiglate is a rain forest tree, Fontainea picrosperma, whose limited number and restricted distribution (northeastern Australia) has prompted consideration of designed tree plantations to address supply needs. Here we report a practical laboratory synthesis of tigilanol tiglate that proceeds in 12 steps (12% overall yield, >80% average yield per step) and c
SUBMITTER: Wender PA
PROVIDER: S-EPMC10079359 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA